Investor Class Action Filed Against Impax Laboratories, Inc. for Securities Fraud Violations
Company Name: Impax Laboratories, Inc.
Court: United States District Court for the Northern District of California
Case Number: 16-cv-06557
Judge: The Hon. Haywood Stirling Gilliam Jr.
Class period: Between February 20, 2014 and November 2, 2016
Security Type:

Case Background:

On November 11, 2016, the initial complaint in this securities class action was filed against Impax Laboratories, Inc. (“Impax” or the “Company”), and certain of Impax’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act.  Lead Plaintiff alleges defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Impax and several of its pharmaceutical industry peers colluded to fix generic drug prices; (ii) the foregoing conduct constituted a violation of U.S. antitrust laws; (iii) consequently, Impax’s revenues during the class period were in part the result of illegal conduct; and (iv) as a result of the foregoing, Impax’s public statements were materially false and misleading at all relevant times.

Current Status of Case:

The Court granted defendant’s motion to dismiss on August 12, 2019.  Lead Plaintiff filed an appeal with the Ninth Circuit on September 5, 2019.  This action is still ongoing.

If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at

Please complete this form and list your purchase and sale transaction(s) for Impax Laboratories, Inc.(NASDAQ: IPXL) securities between February 20, 2014 and November 2, 2016, both dates inclusive (the “Class Period”):

You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 844.887.9500, or you may submit your information via email at, or you may click here to print a PDF of this form.

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Impax Laboratories, Inc. (2017) prior to the Class Period?
Are you a current or former employee of Impax Laboratories, Inc. (2017)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
I would like to receive
new case alerts by email